suPARnostic® will now be available for clinical decision making in the University Hospital of Montpellier, France.
It will be the first hospital in the world to run suPARnostic® TurbiLatex at the Roche cobas 8000 system.

The Hospital has initially been using the suPARnostic® TurbiLatex product to predict outcome in patients with chronic- or acute heart failure. The results have been evaluated with other biomarkers that are specific to this clinical condition and also physiological scores that are typically used to assess the risk of the individual patient and determine the best program for follow up.

There is a big demand for better prognostication of heart failure patients given that many have follow on complications after the initial treatment.

The implementation of the suPARnostic® TurbiLatex product was conducted by Dr Anne-Marie Dupuy in the Laboratory of Biochemistry and Hormonology, which is headed by Professor Jean Paul Cristol. The laboratory has a 24/7 days service for blood samples from all departments within the hospital and runs approx. 500,000 blood samples annually, and suPARnostic® TurbiLatex will now be available for all departments in the hospital including the Emergency Department.

Professor Jean Paul Cristol says; ”We see an increasing need for better prognostication of patients in all areas of medicine but particularly within cardiovascular diseases. Biomarkers are very important to guide treatment and follow up programs for patients. We are happy to break new ground by being the first hospital in the world to implement suPARnostic® TurbiLatex on the cobas 8000 system, and due to our vast experience with new assays the application of this product went very smooth. We look forward to work with ViroGates to allow for better treatment of patients here at the hospital.”